Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.52 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.52 |
| ▸ | SYK | P43405 | 10/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.47 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | DHODH | Q02127 | 1/20 | 0.45 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2083064 | 0.89 | CYP4F2 (0.54) | CYP4F2CYP4A11SYKFFAR1CYP4Z1 | |
| SCHEMBL4611312 | 0.84 | FFAR1 (0.64) | SYKFFAR1FFAR4 | |
| SCHEMBL13159630 | 0.82 | CYP4F2 (0.66) | CYP4F2CYP4A11SYKFFAR1CYP4Z1 | |
| SCHEMBL8567926 | 0.82 | CYP4F2 (0.57) | CYP4F2CYP4A11SYKFFAR1CYP4Z1 | |
| SCHEMBL2772418 | 0.81 | CYP4F2 (0.68) | CYP4F2CYP4A11FFAR1CYP4Z1HRH3 | |
| SCHEMBL11894639 | 0.79 | CYP4F2 (0.70) | CYP4F2CYP4A11SYKFFAR1CYP4Z1 | |
| SCHEMBL30540945 | 0.78 | FFAR1 (0.55) | CYP4F2CYP4A11SYKFFAR1HRH3 | |
| SCHEMBL8903063 | 0.77 | TDP1 (0.56) | CYP4F2CYP4A11SYKFFAR1FFAR4 | |
| SCHEMBL2086697 | 0.76 | CYP17A1 (0.46) | SYKFFAR1HRH3MGLLFFAR4 | |
| SCHEMBL23512483 | 0.76 | CYP4F2 (0.70) | CYP4F2CYP4A11SYKFFAR1CYP4Z1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7863332-B2 | Biaromatic compound activators of PPARγ receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-01-04 | — | — | US | disclosed |
| EP-1781297-B1 | NOVEL BIAROMATIC COMPOUNDS THAT ACTIVATE PPAR TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RES & DEV (FR) | 2008-10-15 | — | — | EP | disclosed |
| US-20070213336-A1 | Biaromatic compound activators of ppargamma receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-09-13 | — | — | US | disclosed |
| EP-1781297-A1 | NOVEL BIAROMATIC COMPOUNDS THAT ACTIVATE PPAR TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | Galderma Research & Development, S.N.C. (FR) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006018326-A1 | NOVEL BIAROMATIC COMPOUNDS THAT ACTIVATE PPAR TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213336-A1 | Biaromatic compound activators of ppargamma receptors and cosmetic/pharmaceutical compositions comprised thereof | PPARG, PPARA, PPARD | CYP4F2 601/4885CYP4A11 258/4885SYK 4499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.